<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343378</url>
  </required_header>
  <id_info>
    <org_study_id>2019/291/OB</org_study_id>
    <nct_id>NCT04343378</nct_id>
  </id_info>
  <brief_title>Prediction of Abatacept Discontinuation Using Test Reflecting Immunological Remission in Rheumatoid Arthritis</brief_title>
  <acronym>PADIRRA</acronym>
  <official_title>Prediction of Abatacept Discontinuation Using Test Reflecting Immunological Remission in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to identify a panel of immunological molecular and cellular
      biomarkers able to predict the success of major dose-reduction or discontinuation of
      abatacept in rheumatoid arthritis patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parameters studied at different time points (before initiation of abatacept if sample is
      available in our biocollection; prior to dose tapering; prior to discontinuation) ACPA
      (anti-citrullinated proteins antibodies) repertoire

      -IgG (Immunoglobulins G) and/or IgA auto-antibodies repertoire directed against major
      epitopes of well-known autoantigens

      B cell repertoire B cell repertoire and transcriptome of regulatory B lymphocytes, memory B
      cells and B cells targeting specific autoantigens.

      Analysis of type I interferon signature Expression levels of 7 type I interferon (IFN)
      response genes will be determined to calculate on type I IFN score
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>relapse</measure>
    <time_frame>from date of inclusion until the date of documented flare assessed up to 24 months</time_frame>
    <description>Increase of DAS(Disease Activity Score)28 ESR (or CRP) &gt; 3.2 at 2 consecutive time points.</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum; PAXgene tubes, cellular samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All ACPA + RA patients from the rheumatology department of Rouen University Hospital
        receiving IV (intravenous) or SC (subcutaneous) abatacept (according to the usual scheme or
        having started tapering) and in deep remission (as defined previously) will be included.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatoid arthritis (RA) patients (&gt; pr = 18 years) fulfilling the 2010 ACR/EULAR
             criteria

          -  Associated to high levels (&gt; 3 x upper limit of normal in UA/ml) of ACPA measured by
             the usual anti-CCP(cyclic citrullinated proteins)2 test at the start of abatacept
             treatment

          -  Receiving IV (intravenous) or SC (subcutaneous) abatacept alone or in combination with
             a conventional Disease Modyfying AntiRheumatic Drugs (cDMARD) (methotrexate,
             leflunomide, sulfasalasin in monotherapy or in combination) according to the usual
             scheme or in tapering phase

          -  Without intra-articular injections of corticosteroids during the last 6 months prior
             to down-titration of abatacept

          -  Having discontinued corticosteroids at he time of entrance in the study

          -  In deep remission (Disease Activity Score (DAS) 28 ESR (or CRP) &lt; 2.6 without clinical
             synovitis) since at least 1 year

          -  In sonographic remission at the time of enrollment (absence of PD (Power
             Doppler)-positive synovitis on 28 joints defined by a score &lt; 2 on a 0-3
             semi-quantitative scale for each joint)

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  RA negative for ACPA (anti-citrullinated proteins antibodies) or not fulfilling
             ACR/EULAR criteria

          -  Abatacept discontinuation due to serious adverse event, loss of efficacy or pregnancy
             project
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier VITTECOQ, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>therapy discontinuation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

